timothy sykes logo
CVS Health Stock Rises as Aetna Expands Oncology Bundles Thumbnail
G Google News

CVS Health Stock Rises as Aetna Expands Oncology Bundles

MATT MONACO•UPDATED SEP. 25, 2026, 4:38 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

CVS Health Corporation stocks have been trading up by 4.8 percent following upbeat sentiment around its healthcare services growth prospects.

What Traders Need To Know

  • Bernstein lifted its price target to $112 from $106, with the Street’s mean target at $114.58 versus a current CVS price near $94, signaling room for upside.
  • Aetna is scaling its bundled oncology prior authorization program to all cancer types for Medicaid now, with Medicare and commercial rollout planned in 2027.
  • Over $5M went into Dallas’s Tabor Village housing project as CVS Health Corporation leans into social-determinants-of-health and community-based care.
  • Ongoing funding in Chicago’s North Lawndale, including an $18M Grace Manor commitment and new grant support, shows sustained neighborhood-level investment.
  • Targeted MMR vaccination efforts in Tennessee highlight CVS’s role as a front-line public-health and immunization provider.

Candlestick Chart

Weekly Update Sep 21 – Sep 25, 2026: On Friday, September 25, 2026 CVS Health Corporation stock [NYSE: CVS] is trending up by 4.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

CVS Health holds a defensible integrated healthcare position with $402B in revenue and mid‑single‑digit top-line CAGR, but operates on razor-thin margins (EBIT ~2.1%, net ~1.2%), well below best-in-class payers. Returns on equity and assets (6.2% and 1.9%) trail managed-care peers, reflecting capital intensity and goodwill-heavy balance sheet. That said, cash generation is strong: LTM cash flow per share of $11.56 and FCF of ~$5.7B support a 3.1% dividend yield, modest leverage (D/E 0.96), and a very undemanding 0.26x sales and ~4.3x cash flow valuation.

Technically, CVS is breaking out of a short-term consolidation with a sharp move from the mid‑80s to a 89.38 close, establishing a higher high versus the 87–88 congestion zone. Weekly structure now shows emerging upside momentum after defending the 85 level multiple sessions; buyers consistently stepped in on dips with expanding volume into the 89 handle. Dominant trend is turning bullish. Actionable level: 87.00–87.20 is now key support; use that zone for entries with a tight stop below 85.

Near-term catalysts skew favorable versus Healthcare Plans peers: Aetna’s expansion of bundled oncology prior auth should improve provider satisfaction and retention while modestly enhancing medical cost management, and Lyric’s claims-control tools reinforce that theme. Community and women’s health initiatives, plus retail vaccination responsiveness, strengthen the brand and traffic versus smaller medical-service competitors. With consensus targets around $114 and recent upgrades, I see upside to $110 over 12–18 months, with support near $85 and resistance at $100.

More Breaking News

Quick Financial Overview

CVS Health Corporation is trading around the mid-$80s to high-$80s area on the weekly chart, with a recent push up to about $89.38 after bouncing from lows near $84.95. That move reflects steady buying interest after brief dips, and it comes while Wall Street targets sit much higher, with Bernstein at $112 and the average near $114.58. For traders, that gap between price and targets, combined with firm recent closes, frames CVS as a potential swing candidate rather than a broken story.

Intraday, CVS showed a controlled grind higher. Price opened the regular session around $85.35, briefly tested the mid-$84s, then trended up most of the day, finishing near the highs around $89.38. Pullbacks were shallow and kept making higher lows, which is classic intraday trend strength. This kind of orderly uptrend, without violent reversals, often signals real institutional accumulation rather than just day-trader noise.

Fundamentally, CVS Health posted quarterly revenue of about $106.1B with gross margin near 14.2% and an EBIT margin around 2.1% — thin, but typical for managed care and retail pharmacy. Free cash flow of roughly $5.65B against a dividend rate of $2.66 per share (around a 3.1% yield) shows the cash engine is strong enough to cover payouts and still deleverage. Debt is meaningful, with total debt-to-equity near 0.96 and current ratio at 0.9, so balance-sheet discipline matters. Valuation looks undemanding on sales and cash flow with price-to-sales near 0.26 and price-to-cash-flow around 4.3, even if the P/E around 22.7 bakes in some recovery expectations.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”